Mejías Trueba Marta, Alonso Moreno Marta, Puñal Garrido Noemi, Soriano Martínez Maria
Pharmacy Service, Instituto de Biomedicina de Sevilla (IBIS), Hospital Universitario Virgen del Rocío, Seville, Spain.
Pharmacy Service, Hospital Universitario Virgen del Rocío, Seville, Spain.
Eur J Case Rep Intern Med. 2020 Jul 29;7(10):001668. doi: 10.12890/2020_001668. eCollection 2020.
Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is a rare hereditary systemic autoinflammatory disease (SAID). Treatment is based on corticosteroids, but often requires the addition of a biologic drug (anti-TNF agent, IL-1 receptor antagonist, etc) to achieve symptom control. The addition of the second drug is not clearly defined and must take into account the characteristics and preferences of the patient. We describe a patient with TRAPS and an allergic reaction to anakinra which was difficult to manage clinically while alternative treatment was being identified.
Treatment of tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) often requires adding a biologic drug to corticosteroids to achieve the best efficacy.Currently, IL-1 receptor antagonists are considered the first line of treatment in TRAPS.The most frequent adverse effect of anakinra is a reaction at the injection site.Canakinumab has shown better response compared to placebo in the treatment of TRAPS.
肿瘤坏死因子（TNF）受体相关周期性综合征（TRAPS）是一种罕见的遗传性全身性自身炎症性疾病（SAID）。治疗以皮质类固醇为基础，但通常需要加用生物药物（抗TNF药物、IL-1受体拮抗剂等）以实现症状控制。第二种药物的添加尚无明确规定，必须考虑患者的特征和偏好。我们描述了一名患有TRAPS且对阿那白滞素过敏的患者，在确定替代治疗方案时，其临床管理困难。
肿瘤坏死因子（TNF）受体相关周期性综合征（TRAPS）的治疗通常需要在皮质类固醇基础上加用生物药物以达到最佳疗效。目前，IL-1受体拮抗剂被认为是TRAPS的一线治疗药物。阿那白滞素最常见的不良反应是注射部位反应。在TRAPS治疗中，卡那单抗与安慰剂相比显示出更好的疗效。
